Just wanted to touch on, you guys cited some timing around renewals that may have impacted ACV growth during the quarter. If I remind everyone, we pointed the equivalent of page 20 in Q1 indicated we expected to see a pullback in recurring organic growth in Q2. The organic ACV growth of about a percent and a half in the end of June is generally in line with our first half organic growth for subscription revenues at about 1.2%. Just how you're thinking about how it could contribute to growth, and is it included in the subscription or is there an upcharge for it?
We are very pleased with the progress so far, which is the AI enablement of our existing product is a source of revenue for new logos, new products, and improving retention. For example, Web of Science Research Intelligence, definitely a new revenue stream. IPOne that I've been talking about, and we are very excited about IPOne, definitely a new revenue stream. Some will come, Nexus Connect, another product from A&G which involve MCP, and we see the customers industry segment including the life science, how they want to consume our data, our proprietary data.
I just had a question on the expectation for acceleration of organic growth. I think just going into 2027, I guess maybe just is that 100 basis points for the full year as well in 2027, or how we should think about that? We believe that we're going to improve recurring in the second half of the year for IP as well, with a great new momentum. We do believe IP will be turned around faster with Simon in place, and with the great assets, annuity, software intelligence that we have, and with the AI innovation I've mentioned.